(VIANEWS) – W.P. Carey REIT (WPC), OFG Bancorp (OFG), The York Water Company (YORW) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. W.P. Carey REIT (WPC)
21% sales growth and 8.91% return on equity
W. P. Carey ranks among the largest net lease REITs with an enterprise value of approximately $18 billion and a diversified portfolio of operationally-critical commercial real estate that includes 1,215 net lease properties covering approximately 142 million square feet as of September 30, 2020. For nearly five decades, the company has invested in high-quality single-tenant industrial, warehouse, office, retail and self-storage properties subject to long-term net leases with built-in rent escalators. Its portfolio is located primarily in the U.S. and Northern and Western Europe and is well-diversified by tenant, property type, geographic location and tenant industry.
Earnings Per Share
As for profitability, W.P. Carey REIT has a trailing twelve months EPS of $3.56.
PE Ratio
W.P. Carey REIT has a trailing twelve months price to earnings ratio of 17.96. Meaning, the purchaser of the share is investing $17.96 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.91%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jun 28, 2023, the estimated forward annual dividend rate is 4.28 and the estimated forward annual dividend yield is 6.69%.
2. OFG Bancorp (OFG)
15.6% sales growth and 16.9% return on equity
OFG Bancorp, a financial holding company, provides a range of banking and financial services. It operates through three segments: Banking, Wealth Management, and Treasury. The company offers checking and savings accounts, as well as time deposit products; commercial, consumer, auto leasing, and mortgage lending services; financial planning and insurance services; and corporate and individual trust, and retirement services. In addition, it provides securities brokerage and investment advisory services, including various investment alternatives, such as tax-advantaged fixed income securities, mutual funds, stocks, and bonds to retail and institutional clients; and separately-managed accounts and mutual fund asset allocation programs. Further, the company engages in the insurance agency and reinsurance businesses; administration and servicing of retirement plans; various treasury-related functions with an investment portfolio consisting of mortgage-backed securities, obligations of U.S. government sponsored agencies, and U.S. Treasury securities and money market instruments; and management and participation in public offerings and private placements of debt and equity securities. Additionally, it offers money management and investment banking services; and engages in the asset/liability management activities, such as purchases and sales of investment securities, interest rate risk management, derivatives, and borrowings. OFG Bancorp was founded in 1964 and is headquartered in San Juan, Puerto Rico.
Earnings Per Share
As for profitability, OFG Bancorp has a trailing twelve months EPS of $3.74.
PE Ratio
OFG Bancorp has a trailing twelve months price to earnings ratio of 8.03. Meaning, the purchaser of the share is investing $8.03 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.9%.
Volume
Today’s last reported volume for OFG Bancorp is 219059 which is 3.03% below its average volume of 225914.
Moving Average
OFG Bancorp’s value is below its 50-day moving average of $30.44 and above its 200-day moving average of $27.67.
Yearly Top and Bottom Value
OFG Bancorp’s stock is valued at $30.03 at 11:22 EST, way under its 52-week high of $34.30 and way above its 52-week low of $22.34.
3. The York Water Company (YORW)
12.5% sales growth and 10.09% return on equity
The York Water Company impounds, purifies, and distributes drinking water. It owns and operates two wastewater collection systems; five wastewater collection and treatment systems; and two reservoirs, including Lake Williams and Lake Redman, which hold approximately 2.2 billion gallons of water. The company also operates a 15-mile pipeline from the Susquehanna River to Lake Redman; and owns nine groundwater wells that supply water to customers in the Adams County. It serves customers in the fixtures and furniture, electrical machinery, food products, paper, ordnance units, textile products, air conditioning systems, laundry detergents, barbells, and motorcycle industries in 51 municipalities within three counties in south-central Pennsylvania. The York Water Company was incorporated in 1816 and is based in York, Pennsylvania.
Earnings Per Share
As for profitability, The York Water Company has a trailing twelve months EPS of $1.46.
PE Ratio
The York Water Company has a trailing twelve months price to earnings ratio of 28.38. Meaning, the purchaser of the share is investing $28.38 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.09%.
Volume
Today’s last reported volume for The York Water Company is 21065 which is 53.08% below its average volume of 44904.
4. Vertex Pharmaceuticals (VRTX)
9.3% sales growth and 24.56% return on equity
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Earnings Per Share
As for profitability, Vertex Pharmaceuticals has a trailing twelve months EPS of $12.93.
PE Ratio
Vertex Pharmaceuticals has a trailing twelve months price to earnings ratio of 26.97. Meaning, the purchaser of the share is investing $26.97 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.56%.
5. Aercap Holdings N.V. Ordinary Shares (AER)
6.2% sales growth and 11.88% return on equity
AerCap Holdings N.V., an aircraft leasing company, engages in the lease, financing, sale, and management of commercial aircraft and engines in China, the United States, Ireland, and internationally. The company offers aircraft asset management services, including remarketing aircraft; collecting rental and maintenance rent payments, monitoring aircraft maintenance, monitoring and enforcing contract compliance, and accepting delivery and redelivery of aircraft; and conducting ongoing lessee financial performance reviews. Its aircraft asset management services also comprise periodically inspecting the leased aircraft; coordinating technical modifications to aircraft to meet new lessee requirements; conducting restructuring negotiations in connection with lease defaults; repossessing aircraft; arranging and monitoring insurance coverage; registering and de-registering aircraft; arranging for aircraft and aircraft engine valuations; and providing market research services. The company also provides cash management services, including treasury services, such as the financing, refinancing, hedging, and ongoing cash management of vehicles; and administrative services comprising accounting and corporate secretarial services consisting of the preparation of budgets and financial statements. As of December 31, 2018, it had a portfolio of 1,421 owned, managed, or on order aircraft. AerCap Holdings N.V. was founded in 1995 and is headquartered in Dublin, Ireland.
Earnings Per Share
As for profitability, Aercap Holdings N.V. Ordinary Shares has a trailing twelve months EPS of $7.8.
PE Ratio
Aercap Holdings N.V. Ordinary Shares has a trailing twelve months price to earnings ratio of 7.89. Meaning, the purchaser of the share is investing $7.89 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.88%.
Volume
Today’s last reported volume for Aercap Holdings N.V. Ordinary Shares is 511227 which is 44.12% below its average volume of 914923.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Aercap Holdings N.V. Ordinary Shares’s EBITDA is 8.18.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is 7.2% and a drop 7.9% for the next.
